David A Fruman

List of Publications by Citations

104 papers	10,210 citations	48 h-index	101 g-index
186 ext. papers	11,325 ext. citations	10.4 avg, IF	6.51 L-index

#	Paper	IF	Citations
104	Phosphoinositide kinases. *Annual Review of Biochemistry*, **1998**, 67, 481-507	29.1	1283
103	PI3K and cancer: lessons, challenges and opportunities. *Nature Reviews Drug Discovery*, **2014**, 13, 140-56	64.1	1127
102	The PI3K Pathway in Human Disease. *Cell*, **2017**, 170, 605-635	56.2	1030
101	Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. *EMBO Journal*, **1998**, 17, 1961-72	13	399
100	Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. *Science*, **1997**, 276, 1848-50	33.3	372
99	Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. *Nature Medicine*, **2010**, 16, 205-13	50.5	299
98	Phosphoinositide 3-kinase: diverse roles in immune cell activation. *Annual Review of Immunology*, **2004**, 22, 563-98	34.7	289
97	Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. *Nature Genetics*, **2000**, 26, 379-82	36.3	251
96	Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. *Molecular and Cellular Biology*, **2002**, 22, 965-77	4.8	230
95	Immunophilins in protein folding and immunosuppression. *FASEB Journal*, **1994**, 8, 391-400	0.9	220
94	Phosphoinositide 3-kinase in immunological systems. *Seminars in Immunology*, **2002**, 14, 7-18	10.7	179
93	Fine tuning the immune response with PI3K. *Immunological Reviews*, **2009**, 228, 253-72	11.3	174
92	Reduced expression of the murine p85 subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. *Journal of Clinical Investigation*, **2002**, 109, 141-149	15.9	172
91	PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. *Biochemical Journal*, **2012**, 442, 465-81	3.8	168
90	Xid-like phenotypes: a B cell signalosome takes shape. *Immunity*, **2000**, 13, 1-3	32.3	167
89	Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. *Journal of Biological Chemistry*, **2003**, 278, 48453-66	5.4	164
88	Regulation of quiescence in lymphocytes. *Trends in Immunology*, **2003**, 24, 380-6	14.4	160

87	FOXO1 regulates L-Selectin and a network of human T cell homing molecules downstream of phosphatidylinositol 3-kinase. *Journal of Immunology*, **2008**, 181, 2980-9	5.3	141
86	SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. *Journal of Biological Chemistry*, **1999**, 274, 32662-6	5.4	139
85	Akt and mTOR in B Cell Activation and Differentiation. *Frontiers in Immunology*, **2012**, 3, 228	8.4	127
84	ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. *Cancer Research*, **2005**, 65, 2047-53	10.1	126
83	Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. *Journal of Clinical Investigation*, **2008**, 118, 3038-50	15.9	119
82	PI3K□inhibitors in cancer: rationale and serendipity merge in the clinic. *Cancer Discovery*, **2011**, 1, 562-72	24.4	117
81	Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E2298-307	11.5	113
80	Structural organization and alternative splicing of the murine phosphoinositide 3-kinase p85 alpha gene. *Genomics*, **1996**, 37, 113-21	4.3	110
79	Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors. *Blood*, **2004**, 104, 784-7	2.2	109
78	Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling. *Current Opinion in Immunology*, **2004**, 16, 314-20	7.8	107
77	Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. *Molecular and Cellular Biology*, **2005**, 25, 2593-606	4.8	103
76	Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas. *European Journal of Immunology*, **1992**, 22, 2513-7	6.1	92
75	Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. *Blood*, **2004**, 103, 4268-75	2.2	80
74	Silencing c-Myc translation as a therapeutic strategy through targeting PI3K□and CK1□in hematological malignancies. *Blood*, **2017**, 129, 88-99	2.2	74
73	Proliferation and survival of activated B cells requires sustained antigen receptor engagement and phosphoinositide 3-kinase activation. *Journal of Immunology*, **2003**, 170, 5851-60	5.3	72
72	Impaired kit- but not FcepsilonRI-initiated mast cell activation in the absence of phosphoinositide 3-kinase p85alpha gene products. *Journal of Biological Chemistry*, **2000**, 275, 6022-9	5.4	68
71	FOXO transcription factors cooperate with delta EF1 to activate growth suppressive genes in B lymphocytes. *Journal of Immunology*, **2006**, 176, 2711-21	5.3	67
70	Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli. *European Journal of Immunology*, **2007**, 37, 2923-36	6.1	65

69	Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 16882-7	11.5	63
68	FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. *European Journal of Immunology*, **1995**, 25, 563-71	6.1	59
67	KLF4 is a FOXO target gene that suppresses B cell proliferation. *International Immunology*, **2008**, 20, 671-81	4.9	58
66	Enhanced T cell proliferation in mice lacking the p85beta subunit of phosphoinositide 3-kinase. *Journal of Immunology*, **2004**, 172, 6615-25	5.3	57
65	Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 359-64	11.5	54
64	Selective inhibition of phosphoinositide 3-kinase p110δ preserves lymphocyte function. *Journal of Biological Chemistry*, **2013**, 288, 5718-31	5.4	53
63	KLF4 suppresses transformation of pre-B cells by ABL oncogenes. *Blood*, **2007**, 109, 747-55	2.2	52
62	PI3K signaling controls cell fate at many points in B lymphocyte development and activation. *Seminars in Cell and Developmental Biology*, **2004**, 15, 183-97	7.5	51
61	T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. *Blood*, **2007**, 109, 2894-902	2.2	50
60	Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha. *Developmental Dynamics*, **2009**, 238, 2670-9	2.9	49
59	The SH2 domain-containing inositol 5'phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during FcgammaRIIb1-mediated inhibition of B cell receptor signaling. *Journal of Biological Chemistry*, **1999**, 274, 7489-94	5.4	49
58	PI3Ks in lymphocyte signaling and development. *Current Topics in Microbiology and Immunology*, **2010**, 346, 57-85	3.3	48
57	Analysis of the major patterns of B cell gene expression changes in response to short-term stimulation with 33 single ligands. *Journal of Immunology*, **2004**, 173, 7141-9	5.3	48
56	mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E5076-85	11.5	43
55	The 4E-BP-eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes. *Science Signaling*, **2016**, 9, ra57	8.8	43
54	Target of rapamycin signaling in leukemia and lymphoma. *Clinical Cancer Research*, **2010**, 16, 5374-80	12.9	40
53	Targeting TOR dependence in cancer. *Oncotarget*, **2010**, 1, 69-76	3.3	40
52	Statins enhance efficacy of venetoclax in blood cancers. *Science Translational Medicine*, **2018**, 10,	17.5	39

51	YAP-mediated mechanotransduction tunes the macrophage inflammatory response. *Science Advances*, **2020**, 6,	14.3	37
50	Class IA phosphoinositide 3-kinase modulates basal lymphocyte motility in the lymph node. *Journal of Immunology*, **2007**, 179, 2261-9	5.3	36
49	Immune regulation by rapamycin: moving beyond T cells. *Science Signaling*, **2009**, 2, pe25	8.8	35
48	Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1. *PLoS ONE*, **2014**, 9, e88865	3.7	33
47	Altered signaling and cell cycle regulation in embryonal stem cells with a disruption of the gene for phosphoinositide 3-kinase regulatory subunit p85alpha. *Journal of Biological Chemistry*, **2003**, 278, 5099-108	5.4	33
46	Foxo1 regulates marginal zone B-cell development. *European Journal of Immunology*, **2010**, 40, 1890-6	6.1	31
45	Regulatory subunits of class IA PI3K. *Current Topics in Microbiology and Immunology*, **2010**, 346, 225-44	3.3	29
44	Targeting mTOR for the treatment of B cell malignancies. *British Journal of Clinical Pharmacology*, **2016**, 82, 1213-1228	3.8	29
43	Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in rearranged and/or driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. *Oncotarget*, **2018**, 9, 8027-8041	3.3	28
42	Altered splenic B cell subset development in mice lacking phosphoinositide 3-kinase p85alpha. *International Immunology*, **2004**, 16, 1789-98	4.9	27
41	mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. *Oncotarget*, **2015**, 6, 2088-100	3.3	25
40	p85beta phosphoinositide 3-kinase regulates CD28 coreceptor function. *Blood*, **2009**, 113, 3198-208	2.2	24
39	Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth. *Nature Communications*, **2020**, 11, 3326	17.4	23
38	MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. *Oncotarget*, **2016**, 7, 55083-55097	3.3	23
37	An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. *Blood*, **2020**, 135, 2337-2353	2.2	22
36	MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. *Oncotarget*, **2015**, 6, 35202-17	3.3	21
35	Achieving cancer cell death with PI3K/mTOR-targeted therapies. *Annals of the New York Academy of Sciences*, **2013**, 1280, 15-8	6.5	21
34	Frontline: The p85alpha isoform of phosphoinositide 3-kinase is essential for a subset of B cell receptor-initiated signaling responses. *European Journal of Immunology*, **2004**, 34, 2968-76	6.1	18

33	Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism. *Molecular Cancer Therapeutics*, **2018**, 17, 1781-1792	6.1	16
32	Cancer therapy: staying current with AMPK. *Biochemical Journal*, **2008**, 412, e3-5	3.8	16
31	Measuring phosphorylated Akt and other phosphoinositide 3-kinase-regulated phosphoproteins in primary lymphocytes. *Methods in Enzymology*, **2007**, 434, 131-54	1.7	16
30	Viral/Nonviral Chimeric Nanoparticles To Synergistically Suppress Leukemia Proliferation via Simultaneous Gene Transduction and Silencing. *ACS Nano*, **2016**, 10, 8705-14	16.7	16
29	Role of phosphoinositide 3-kinase signaling in autoimmunity. *Autoimmunity*, **2007**, 40, 433-41	3	15
28	The Selective Phosphoinoside-3-Kinase p110 Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation. *Frontiers in Immunology*, **2017**, 8, 747	8.4	14
27	INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency. *Cancer Discovery*, **2015**, 5, 697-700	24.4	13
26	The p85beta regulatory subunit of phosphoinositide 3-kinase has unique and redundant functions in B cells. *Autoimmunity*, **2009**, 42, 447-58	3	12
25	Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling. *Journal of Clinical Investigation*, **2014**, 124, 3688-90	15.9	11
24	Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. *PLoS ONE*, **2014**, 9, e99486	3.7	10
23	B cell receptor signaling: picky about PI3Ks. *Science Signaling*, **2010**, 3, pe25	8.8	10
22	The mTORC1/4E-BP/eIF4E Axis Promotes Antibody Class Switching in B Lymphocytes. *Journal of Immunology*, **2019**, 202, 579-590	5.3	10
21	Context-Specific Function of S6K2 in Th Cell Differentiation. *Journal of Immunology*, **2016**, 197, 3049-3058	5.3	9
20	mTOR inhibition enhances efficacy of dasatinib in -rearranged Ph-like B-ALL. *Oncotarget*, **2018**, 9, 6562-6571	5.3	8
19	Genetics. Can cancer drugs treat immunodeficiency?. *Science*, **2013**, 342, 814-5	33.3	7
18	mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph and Ph-like B-ALL. *Molecular Cancer Therapeutics*, **2017**, 16, 1942-1953	6.1	6
17	Targeting the Mevalonate Pathway in Cancer. *Trends in Cancer*, **2021**, 7, 525-540	12.5	6
16	A cross-institutional analysis of the effects of broadening trainee professional development on research productivity. *PLoS Biology*, **2021**, 19, e3000956	9.7	5

List of Publications

15	mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL. *Blood*, **2016**, 128, 2763-2763	2.2	4
14	Targeting PI3K-Gamma in Non-Hodgkin Lymphoma. *Journal of Clinical Oncology*, **2019**, 37, 932-934	2.2	3
13	The CD11a and Endothelial Protein C Receptor Marker Combination Simplifies and Improves the Purification of Mouse Hematopoietic Stem Cells. *Stem Cells Translational Medicine*, **2018**, 7, 468-476	6.9	3
12	mTOR signaling: new networks for ALL. *Blood*, **2016**, 127, 2658-9	2.2	2
11	Reduced eIF4E function impairs B-cell leukemia without altering normal B-lymphocyte function. *IScience*, **2021**, 24, 102748	6.1	2
10	A Case for Phosphoinositide 3-Kinase-Targeted Therapy for Infectious Disease. *Journal of Immunology*, **2020**, 205, 3237-3245	5.3	1
9	Targeting of a Novel MNK-eIF4E-b-Catenin Axis in Blast Crisis Chronic Myelogenous Leukemia Inhibits Leukemia Stem Cell Function. *Blood*, **2011**, 118, 963-963	2.2	1
8	Keys to successful implementation of a professional development program **2020**, 129-137		1
7	Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax. *British Journal of Cancer*, **2021**, 124, 1098-1109	8.7	1
6	Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition. *Scientific Reports*, **2021**, 11, 21689	4.9	0
5	Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia. *Frontiers in Oncology*, **2021**, 11, 673213	5.3	0
4	Phosphoinositide 3-Kinases **2010**, 1049-1060		
3	PI 3-KINASE KNOCKOUT MICE: ROLE OF p85IN B CELL DEVELOPMENT AND PROLIFERATION. *Biochemical Society Transactions*, **1999**, 27, A73-A73	5.1	
2	Statins Potentiate the Cytotoxic Effect of ABT-199 in Diffuse Large B Cell Lymphoma. *Blood*, **2016**, 128, 3969-3969	2.2	
1	The TOR Kinase Inhibitor INK128 Is Effective in Pre-B Acute Lymphoblastic Leukemia Models. *Blood*, **2011**, 118, 2585-2585	2.2	